Article
Translating B cell immunology to the treatment of antibody-mediated allograft rejection - Nature Reviews Nephrology
Rating:
0.0
Views:
38
Likes:
1
Library:
1
Antibody-mediated rejection (AMR), including chronic AMR (cAMR), causes ~50% of kidney allograft losses each year. Despite attempts to develop well-tolerated and effective therapeutics for the management of AMR, to date, none has obtained FDA approval, thereby highlighting an urgent unmet medical need.
Rate This Post
Rate The Educational Value
Rate The Ease of Understanding and Presentation
Interesting or Boring? Rate the Entertainment Value